reports
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 03/05/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Jerôme Bodin
ODDO BHF Small & MIDCAP MORNING NEWS - 05/03/2024
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
- Christophe-Raphaël Ganet
LNA Santé : Q1 2024 revenue: solid - 2024 healthcare tariffs not parti...
>Q1 revenue: robust organic growth - LNA Santé has reported Q1 revenue of € 189.3m, up 6.9% (+6.9% l-f-l). Occupancy rates at cruising speed, excl. hospital care at home, stood at 99%, up 1.6 points vs Q1 2023. LNA reiterated its target for organic growth of 4.5%, i.e. operating income of >€ 750m (i.e. >+4.2%) for an EBITDA margin excl. IFRS of 11% (vs 10.8% in 2023). That said, LNA noted the latest elements relating to 1/ the 2024 tariff campaign for post-acute/...
- Christophe-Raphaël Ganet
LNA Santé : CA T1 2024 : solide – Tarifs sanitaires 2024 peu encourage...
>CA T1 : une croissance organique robuste - LNA Santé publie un CA T1 à 189,3 M€, une hausse de 6,9% (+6,9% à ptc.). Le taux d’occupation des établissements en régime de croisière, hors HAD, ressort à 99%, en hausse de 1,6 point par rapport au T1 2023. LNA renouvelle son objectif de croissance organique à 4,5% soit un CA Exploitation de >750 M€ (ie. >+4,2%) pour une marge d’EBITDA hors IFRS à 11% (vs 10,8% en 2023). Toutefois, LNA insiste sur les derniers élément...
BB Biotech AG: 1 director
A director at BB Biotech AG bought 1,000 shares at 41.450CHF and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Orange Belgium completes its capital increase by contribution in kind ...
Orange Belgium completes its capital increase by contribution in kind – Nethys exchanges its stake in VOO Holding for newly issued shares of Orange Belgium Press releaseBrussels, 2 May 2024Regulated information – Inside information Orange Belgium completes its capital increase by contribution in kind – Nethys exchanges its stake in VOO Holding for newly issued shares of Orange Belgium On 2 May 2024, the shareholders’ meeting of Orange Belgium SA (the “Company”) approved the contribution in kind by Nethys SA (“Nethys”) of its 25% (+ 1 share) stake in VOO Holding SA (“VOO Holding”) to the cap...
Orange Belgium finalise son augmentation de capital par apport en natu...
Orange Belgium finalise son augmentation de capital par apport en nature - Nethys échange sa participation dans VOO Holding contre des actions nouvellement émises d'Orange Belgium Communiqué de presseBruxelles, le 2 mai 2024Information réglementée – informations confidentielles Orange Belgium finalise son augmentation de capital par apport en nature - Nethys échange sa participation dans VOO Holding contre des actions nouvellement émises d'Orange Belgium Le 2 mai 2024, l'assemblée générale des actionnaires d'Orange Belgium SA (la "Société") a approuvé l'apport en nature par Nethys SA ("...
- ING Helpdesk
Benelux Morning Notes
Aedifica: First sign of portfolio valuation stabilization. ArcelorMittal: Solid 1Q24 EBITDA beat, softer FCF reflects WC and CAPEX phasing. Belgian telcos: Peer Telenet 1Q24 results, still weak commercial performance. dsm-firmenich AG: Vita-still not-min. IBA: Contract to install a P1 system in Connecticut. KPN: VodafoneZiggo 1Q24 results confirm fixed losses, mobile weaker QoQ. Shell plc: Good start to the year
PGS ASA: Annual Report 2023
PGS ASA: Annual Report 2023 April 29, 2024, Oslo, Norway: PGS' 2023 annual report can be downloaded from or The Company's 2023 annual financial statements in European Single Electronic Format (ESEF) can be downloaded from the same web pages. For details, contact: Bård Stenberg VP IR & Corporate Communication Mobile: . Attachments
Stef: 1 director
A director at Stef bought 600 shares at 135.377EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Cl...
- Anthony Dick
- Michael Foundoukidis
ODDO BHF Small & MIDCAP MORNING NEWS - 04/26/2024 Date Performance sin...
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
PROX PROXIMUS SA DE DROIT PUBLIC
SOP SOPRA STERIA GROUP SA
BFIT BASIC-FIT NV
NXI NEXITY SA CLASS A
MF WENDEL SE
SBS STRATEC SE
KORI KORIAN SA
STF STEF
ALCLA CLASQUIN SA
ASY ASSYSTEM SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
SRP SRP GROUPE SA
MTU MANITOU BF SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
TIETO TIETOEVRY OYJ
ARCAD ARCADIS NV
SESL SES-IMAGOTAG SA
LIGHT SIGNIFY NV
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
CSM CORBION NV
VLTSA VOLTALIA
IBG IBERPAPEL GESTION S.A.
TEC TECHNIPFMC PLC
FTG111 FLATEXDEGIRO AG
BFSA BEFESA SA
SAB BANCO DE SABADELL SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
GRP GREENCOAT RENEWABLES
- Anthony Dick
- Michael Foundoukidis
ODDO BHF Small & MIDCAP MORNING NEWS - 26/04/2024
Deutz is a leading non-captive engine manufacturer for a wide range of customer industries with a strong and very well-known brand. The company will enter a profitable growth period soon (CAGR 2023-26e sales 8%, EPS 18%). We initiate coverage with an Outperform rating and a target price of € 7.9, reflecting >40% upside from here. - ...
PROX PROXIMUS SA DE DROIT PUBLIC
SOP SOPRA STERIA GROUP SA
BFIT BASIC-FIT NV
NXI NEXITY SA CLASS A
MF WENDEL SE
SBS STRATEC SE
KORI KORIAN SA
STF STEF
ALCLA CLASQUIN SA
ASY ASSYSTEM SA
SWP SWORD GROUP SE
CGM CEGEDIM SA
SRP SRP GROUPE SA
MTU MANITOU BF SA
FII LISI SA
GBT GUERBET SA
ATE ALTEN SA
FR VALEO SE
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
MBWS MARIE BRIZARD WINE & SPIRITS SA
SOC SUBSEA 7 S.A.
TIETO TIETOEVRY OYJ
ARCAD ARCADIS NV
SESL SES-IMAGOTAG SA
LIGHT SIGNIFY NV
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
CSM CORBION NV
VLTSA VOLTALIA
IBG IBERPAPEL GESTION S.A.
TEC TECHNIPFMC PLC
FTG111 FLATEXDEGIRO AG
BFSA BEFESA SA
SAB BANCO DE SABADELL SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
GRP GREENCOAT RENEWABLES
- Jeremy Garnier
STEF : Resilient start to the year in an ongoing challenging climate
>Q1 sales of € 1,139m (vs. estimate of € 1,150.1m), up 5.7% or +0.7% lfl - STEF yesterday reported Q1 sales of € 1,139m, up 5.7% or +0.7% like-for-like, close to our estimate of 6.7% growth to € 1,150.1m, reflecting strong resilience despite the slowdown in consumer spending on food in France.Solid momentum supported by international operations - Sales in France (approx. 60% of Q1 sales) remained more or less stable at € 576.7m (vs. estimate of € 585m...
- Christophe-Raphaël Ganet
Guerbet : Q1 2024 revenue: a solid sales performance
>Q1 2024 revenue +8%: solid - Revenue increased by 8.1% in Q1 to € 194.3m (+8.8% cc.) or +7.6% after adjusting the first quarter of 2023 to include Intrasense consolidated since 01/01/2023. The EMEA region posted a decline of 5.8% (-6.2% cc), APAC delivered 20% growth (+26.8% cc) and the Americas recorded 21% growth (+20% cc). The X-ray business turned in +15%, the IRM business -4% and the II business +4.4%.Management confirmed its guidance targets (8% growt...
- Jean-François Granjon
LISI : An excellent start to the year – Included in our Midcap Selecti...
>Q1 sales 12% above our forecasts - Lisi has reported Q1 sales of € 449.3m (€ 430.7m est.) vs € 401.3m, up 11.9% and 12.5% organically. These sales were well above our forecasts, mainly thanks to the excellent showing in aerospace. This was also a good performance in view of the demanding comparison base (+15%). The Aerospace division posted organic growth of 27%, driven by the higher production rate of single-aisle versions of the A320. Full-year target...
- Jeremy Garnier
STEF : Un début d’année résilient face à un contexte toujours challeng...
>CA T1 de 1139 M€ (vs 1150.1 M€e) en hausse de 5.7% (+0.7% lfl) - STEF a publié hier son CA T1 qui est ressorti à 1 139 M€ en hausse de 5.7% (+0.7% lfl) proche de notre attente de 1150.1 M€e (+6.7%e) reflétant une bonne résilience de l’activité face à un ralentissement de la consommation alimentaire en France.Une dynamique solide soutenue par le déploiement à l’international - La France (~60% du CA T1) enregistre un CA quasiment stable à 576.7 M€ (vs ...
- Loic Morvan
- Paul Rouviere
Interparfums management confident for the remainder of 2024
Although guidance has not been upgraded, management remains quite confident for 2024, in view of underlying trends in the US fragrance market and the better-than-expected Lacoste launch. We reiterate our sales forecast of EUR920m, above the company's guidance (EUR880-900m). We cautiously maintain o
- Christophe-Raphaël Ganet
Guerbet : CA T1 2024 : bonne performance commerciale
>CA T1 2024 : +8% : solide - Le CA T1 affiche une hausse de 8,1%, à 194,3 M€ (+8,8% à tcc.) et +7,6% en retraitant le premier trimestre 2023 afin d’intégrer Intrasense, consolidée depuis le 1/1/2023. L’EMEA est en baisse de 5,8% (-6,2% à tcc.), l’APAC progresse de 20% (+26,8% à tcc.) et les Amériques sont en hausse de 21% (+20% à tcc.). Les Rayons-X affichent +15%, l’IRM recule de 4%, et la RIT augmente de 4,4%.Le management a confirmé sa guidance (croissanc...
- Jean-François Granjon
LISI : Un excellent début d’exercice – Titre dans notre Sélection Midc...
>CA T1 supérieur à nos attentes de 12% - Lisi publie un CA T1 de 449.3 M€ (430.7 M€ estimés) vs 401.3 M€ en hausse de 11.9% et +12.5% en organique. Ce CA est largement supérieur à nos attentes principalement du fait des très bonnes performances dans l’aéronautique. Il s’agit de surcroît d’une bonne performance alors que l’effet de référence était soutenu (+15%). Ainsi, la division Aerospace affiche une hausse organique de +27% portée par l’accroissement des cadences d...
EQS-News: BB Biotech presents solid first-quarter results; biotech sto...
EQS-News: BB BIOTECH AG / Key word(s): Interim Report BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates 26.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Media release as at April 26, 2024 Portfolio of BB Biotech AG as at March 31, 2024 BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates Investor sentiment in the biotech space continues to be shaped by the general interest rate environment. Biot...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.